© Globe Newswire
18.12.2024
KDEV
LISTED
STO
Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman
News Preview
STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting....
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
CU6
LISTED
ASX
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
News Preview
Highlights
Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer.The product, termed SAR-bisFAP, has shown strong tumour targeting, retention and pharmacokinetic data to date in pre-clinical...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
ORNBV
LISTED
HEL
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
News Preview
ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET ...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
18.12.2024
TEM
LISTED
NASDAQ
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
News Preview
Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreem...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
18.12.2024
LIVN
LISTED
NASDAQ
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
IMMNOV
LISTED
STO
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
News Preview
LUND, Sweden, Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024.
Immunovia CEO Jeff Borcherding, one of the company's largest sha...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
ICLR
LISTED
NASDAQ
ICON Announces Appointment of Chief Operating Officer
News Preview
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).
Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a numbe...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
HNSA
LISTED
STO
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
News Preview
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the Int...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
HNSA
LISTED
STO
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
News Preview
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the Int...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
SLP
LISTED
NASDAQ
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025.
Manag...
Themefolio
Profiler
Peergroup
© ActuNews
17.12.2024
ALTHX
LISTED
EURONEXT
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
News Preview
Lyon, France – 17 December 2024, 6.15 pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases (the “Company”), today presents an update of its cash position as of 12 December 2024 and its cash flow horizon until the end of the first quarter of 2026.
Total available funds on...
Themefolio
Profiler
Peergroup
© ActuNews
17.12.2024
ALTHX
LISTED
EURONEXT
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANCEMENT
News Preview
Lyon, France – 17 décembre 2024, 18h15 CET - Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares (la « Société »), fait un point sur sa position de trésorerie au 12 décembre 2024 et son horizon de trésorerie jusqu'...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ActuNews
17.12.2024
ALTHX
LISTED
EURONEXT
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS
News Preview
Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two rare neurological diseases notably in Europe.
Theranexus will be eligible to receive up-front payment, development and commercial milestones and double-digit royalties on net sales.
Lyon, France - Madrid, Spain &n...
Themefolio
Profiler
Peergroup
© ActuNews
17.12.2024
ALTHX
LISTED
EURONEXT
THERANEXUS ET EXELTIS (INSUD PHARMA) ANNONCENT UN ACCORD DE LICENCE POUR LA COMMERCIALISATION DU TX01 DE THERANEXUS DANS LE TRAITEMENT DE DEUX MALADIES NEUROLOGIQUES RARES
News Preview
Exeltis obtient une licence exclusive pour commercialiser et distribuer la nouvelle formulation TX01 de Theranexus dans le traitement de deux maladies neurologiques rares, notamment en Europe.
Theranexus recevra un paiement initial, des paiements d'étapes de développement et de commercialisation, ainsi que des redevances &agrav...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
TEM
LISTED
NASDAQ
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.12.2024
ALTHX
LISTED
EURONEXT
Theranexus Presents an Update of its Cash Position and Financing Horizon
News Preview
LYON, FRANCE / ACCESSWIRE / December 17, 2024 / Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases (the "Company"), today presents an update of its cash position as of 12 December 2024 and its cash flow horizon until the end of the first quarter of 2026.Total available funds on 12 December 20...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.12.2024
ALTHX
LISTED
EURONEXT
Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders
News Preview
Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two rare neurological diseases notably in Europe.Theranexus will be eligible to receive up-front payment, development and commercial milestones and double-digit royalties on net sales. LYON, FRANCE and MADRID, SPAIN / ACCESS...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2024
IMCR
LISTED
NASDAQ
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
News Preview
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
SECT_B
LISTED
STO
University of Hartford adopts Sectra's service to improve education and speed up onboarding of radiographers
News Preview
LINKÖPING, Sweden, Dec. 17, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to the University of Hartford in the US. By enabling radiologic technology students, also known as radiographer students, to use the platform, th...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
ORX
LISTED
STO
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
News Preview
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform.The AmorphOX technology has the potential to improve the stability and efficacy of Abera's...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
ORX
LISTED
STO
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
News Preview
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform.The AmorphOX technology has the potential to improve the stability and efficacy of Abera's...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2024
SN
LISTED
LSE
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). ...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
DFTX
LISTED
NASDAQ
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) fo...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
IMMNOV
LISTED
STO
Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.
Jeff Borcherdi...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.12.2024
GXI
LISTED
XETR
FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
News Preview
Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
Innovative combination product of furosemide and on-body device
Ready-to-market device designed, developed and manufactured by Gerresheimer
Patented device technology for precise administration
Düsseldorf, Germany, December 16, 2024. Gerresheimer, an innovative system a......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.12.2024
GXI
LISTED
XETR
FDA erteilt „Tentative Approval“ für Lasix von SQ Innovation® ONYU*
News Preview
Gerresheimer: FDA erteilt „Tentative Approval“ für Lasix von SQ Innovation® ONYU*
Innovatives Kombinationsprodukt aus Furosemid und On-Body Drug Delivery Device
Device marktreif konzipiert, entwickelt und hergestellt von Gerresheimer
Patentierte Gerätetechnologie für präzise Verabreichung
Düsseldorf, 16. Dezember 2024. Gerresheimer, innovativer......
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2024
BAVA
LISTED
CPH
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India
News Preview
COPENHAGEN, Denmark, December 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine with Serum Institute of India Pvt. Ltd. (“SII”). Under the agreement, the companies will undertake a technology transfer of the current manufacturing process for MVA-BN® to SII to enable supply...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
BAVA
LISTED
CPH
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
News Preview
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such....
Themefolio
Profiler
Peergroup
© EQS Newswire
13.12.2024
EUZ
LISTED
XETR
Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
News Preview
Berlin, 13 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge dia......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.12.2024
EUZ
LISTED
XETR
Eckert & Ziegler beantragt Zulassung von GalliaPharm® bei der japanischen Gesundheitsbehörde MHLW
News Preview
Berlin, 13. Dezember 2024. Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), ein führender Anbieter von Isotopentechnologie für die Nuklearmedizin und radiopharmazeutische Anwendungen, gibt die Einreichung ihres GalliaPharm® 68Ge/68Ga Radionuklid-Generators zur Zulassung in Japan bekannt. Dieser Schritt ebnet den Weg für einen breit......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
BAVA
LISTED
CPH
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
News Preview
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management and selected employees in the Bavarian Nordic Group. Members of the Executive Management are granted a mix of performance restricted stock units (Per...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.12.2024
CLBX
LISTED
AIMX
Angle PLC Announces HER2 Presentation at SABCS
News Preview
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUMIndependent findings support ANGLE's HER2 assay development programmePotential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a w...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
ASND
LISTED
NASDAQ
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
News Preview
PDUFA goal date is July 27, 2025 PDUFA goal date is July 27, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
ORNBV
LISTED
HEL
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE12 DECEMBER 2024 at 20.30 EET...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conference in January 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2025:
43rd Annual J.P. Morgan Healthcare Conference
Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST
Location: San Francisco
A live webcast of the presentation wi...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ILM1
LISTED
XETR
Specification of the full-year forecast
News Preview
Adhoc release
Disclosure of inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Specification of the full-year forecast
Berlin, December 12, 2024 – Medios AG (“Medios”) specifies its full-year forecast as follows: The Company expects revenues of c. €1.85 billion (previous year: €1.8 billion which corresponds to ......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ILM1
LISTED
XETR
Konkretisierung der Jahresprognose
News Preview
Ad hoc Veröffentlichung
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Konkretisierung der Jahresprognose
Berlin, 12. Dezember 2024 – Die Medios AG (“Medios”) konkretisiert die Jahresprognose wie folgt: Das Unternehmen erwartet Umsatzerlöse in Höhe von ca. 1,85 Mrd. € (Vorjahr: 1,8 Mrd. €, das......
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
SECT_B
LISTED
STO
Sectra's six-month interim report 2024/2025: Order bookings at a record high
News Preview
LINKÖPING, Sweden, Dec. 12, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) order bookings for the second quarter surpassed SEK 4 billion, exceeding the previous highest level for a single quarter. In other respects, the outcome was dampened by currency effects as well as the ongoing transfor...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
SECT_B
LISTED
STO
Sectra's six-month interim report 2024/2025: Order bookings at a record high
News Preview
LINKÖPING, Sweden, Dec. 12, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) order bookings for the second quarter surpassed SEK 4 billion, exceeding the previous highest level for a single quarter. In other respects, the outcome was dampened by currency effects as well as the ongoing transfor...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Appoints Chief Strategy Officer
News Preview
Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
1SXP
LISTED
XETR
SCHOTT Pharma with strong growth and record margin after solid year-end finish
News Preview
SCHOTT Pharma with strong growth and record margin after solid year-end finish
All 2024 targets met including raised revenue guidance: 12% revenue growth and EBITDA margin of 27.8%, both at constant currencies
Q4 2024 revenues reached EUR 237m; EBITDA margin of 27.9% well above prior year
FY 2024 revenues reached EUR 957m; EBITDA margin of 26.9......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
1SXP
LISTED
XETR
SCHOTT Pharma erreicht starkes Wachstum und Rekordmarge nach gutem Jahresendspurt
News Preview
SCHOTT Pharma erreicht starkes Wachstum und Rekordmarge nach gutem Jahresendspurt
Alle Ziele für 2024 erreicht, einschließlich angehobener Umsatzprognose: 12 % Umsatzwachstum und EBITDA-Marge von 27,8 %, beides währungsbereinigt
Q4 2024 Umsatz bei 237 Mio. Euro; EBITDA-Marge von 27,9 % deutlich über dem Vorjahr
Umsatz für Geschäftsjahr 2024 bei......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
DBV
LISTED
EURONEXT
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
News Preview
Châtillon, France, December 11th, 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
11.12.2024 / 16:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
GMAB
LISTED
CPH
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
DFTX
LISTED
NASDAQ
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
IMMNOV
LISTED
STO
Immunovia announces financial calendar for financial year 2025/2026
News Preview
LUND, Sweden, Dec. 11, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026.
Year-End 2024 Report February 25, 2025
Q1 Report, 2025 May 14, 2025
Q2 Report, 2025 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
CELC
LISTED
NASDAQ
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
News Preview
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
SOBI
LISTED
STO
Bulletin from Sobi's Extraordinary General Meeting (EGM)
News Preview
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
SOBI
LISTED
STO
Bulletin from Sobi's Extraordinary General Meeting (EGM)
News Preview
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
GXI
LISTED
XETR
Gerresheimer schließt Akquisition der Blitz LuxCo Sarl, der Holdinggesellschaft der Bormioli Pharma Gruppe, erfolgreich ab
News Preview
Gerresheimer schließt Akquisition der Blitz LuxCo Sarl, der Holdinggesellschaft der Bormioli Pharma Gruppe, erfolgreich ab
Komplementäres Produktportfolio und breite Abdeckung mit Produktionsstandorten in Europa
Stärkung der Marktposition als Komplettanbieter für die Pharma- und Biotech-Branche
Moulded Glass-Geschäft wird strategisch neu aufgese......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
GXI
LISTED
XETR
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
News Preview
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
Complementary product portfolio and broad footprint of production sites in Europe
Strengthening the market position as a full-service provider for the pharma and biotech industry
Strategic reset of Moulded Glass business
Düsseldo......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
EVT
LISTED
XETR
Evotec SE kündigt erste Projekte für den LAB eN² Accelerator mit Novo Nordisk an
News Preview
Novo Nordisk und Evotec wählen drei Projekte von der Boston University, der Harvard University in Zusammenarbeit mit Mass General Brigham und dem Joslin Diabetes Center aus, die im Rahmen von LAB eN² entwickelt werden und sich auf kardiometabolische Erkrankungen konzentrieren
LAB eN² erweitert sich und fügt das Boston Children’s Hospita......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
EVT
LISTED
XETR
Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk
News Preview
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases
LAB eN² is also expanding, adding Boston Children’s Hospital, Boston University, Johns Hopkins University, Jos......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
BAVA
LISTED
CPH
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program
News Preview
COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decision should be viewed in the context of improved visibility around the Company’s Travel Health business, driven by a number of completed and near-term...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
AFX
LISTED
XETR
Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved
News Preview
Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved
Restrictive investment climate and low consumer confidence impact revenue and earnings performance
JENA, 11 December 2024
Carl Zeiss Meditec generated revenue of €2,066.1m in fiscal year 2023/24 (prior year: €2,089.3m), corres......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
SOON
LISTED
SIX
Sonova ernennt neuen Chief Financial Officer
News Preview
Sonova Holding AG
/ Schlagwort(e): Personalie
Sonova ernennt neuen Chief Financial Officer
11.12.2024 / 07:00 CET/CEST
Group Media & Investor Release
Sonova ernennt Elodie Carr-Cingari zur neuen Chief Financial Officer (CFO). Sie wird diese Position spätestens mit Juli 2025 antreten und folgt auf Birgit Conix, die S......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
SOON
LISTED
SIX
Sonova Announces New Chief Financial Officer
News Preview
Sonova Holding AG
/ Key word(s): Personnel
Sonova Announces New Chief Financial Officer
11.12.2024 / 07:00 CET/CEST
Group Media & Investor Release
Sonova appoints Elodie Carr-Cingari as new Chief Financial Officer (CFO), effective no later than July 2025. She succeeds Birgit Conix who is leaving Sonova to pursue non......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
AFX
LISTED
XETR
Carl Zeiss Meditec schließt das Geschäftsjahr 2023/24 mit leicht rückläufigem Umsatz ab – Prognose für bereinigtes EBIT erreicht
News Preview
Carl Zeiss Meditec schließt das Geschäftsjahr 2023/24 mit leicht rückläufigem Umsatz ab – Prognose für bereinigtes EBIT erreicht
Restriktives Investitionsklima und schwache Verbraucherstimmung belasten Umsatz- und Ertragsentwicklung
JENA, 11. Dezember 2024
Carl Zeiss Meditec erreichte im Geschäftsjahr 2023/24 einen Umsatz von rund 2.06......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
